Literature DB >> 11588033

Alterations of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways in the erythropoietin-independent Spi-1/PU.1 transgenic proerythroblasts.

S Barnache1, P Mayeux, B Payrastre, F Moreau-Gachelin.   

Abstract

During the cell transformation processes leading to erythroleukemia, erythroid progenitors often become erythropoietin (Epo)-independent for their proliferation. The biochemical events that could lead an erythroleukemic cell to growth factor-independence were investigated using spi-1 transgenic poerythroblasts. Spi-1/PU.1 is a myeloid and B-cell transcription factor of the ETS family and is activated by insertional mutagenesis during Friend erythroleukemia. Its overexpression in proerythroblasts induces their differentiation arrest without altering their erythropoietin requirement for proliferation (HS1 cells). At a later step, genetic alterations most probably occur allowing spi-1 transgenic poerythroblasts to proliferate in the absence of erythropoietin (HS2 cells). The signaling transduction pathways in HS1 and HS2 proerythroblasts were analyzed. The authors have previously shown that the Jak/STAT pathway was not activated in Epo-independent cells, but remained sensitive to Epo stimulation. In the present study, it is shown that the Epo-independent proliferation of HS2 cells requires active phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. In these cells, PI3K was constitutively associated with the molecular adapters Grb2 and Gab1, and with the phosphatases SHP-2 and SHIP. Moreover, PI3K activity was correlated with the constitutive phosphorylation of serine-threonine protein kinase (AKT) in HS2 cells. Lastly, a constitutive activation of the MAPKs extracellular signal-regulated kinases (ERK1/2) in HS2 cells was observed that occurs in a PI3K-independent manner, but depends strictly on the activity of the protein kinase C (PKC). These results suggest that constitutive activations of PI3K/AKT and PKC/MAPK pathways can act in synergy to lead a proerythroblast to proliferate without Epo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588033     DOI: 10.1182/blood.v98.8.2372

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Functional cross-antagonism between transcription factors FLI-1 and EKLF.

Authors:  Joëlle Starck; Nathalie Cohet; Colette Gonnet; Sandrine Sarrazin; Zina Doubeikovskaia; Alexandre Doubeikovski; Alexis Verger; Martine Duterque-Coquillaud; François Morle
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

2.  Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.

Authors:  Dorothée Selimoglu-Buet; Isabelle Gallais; Nicole Denis; Christel Guillouf; Françoise Moreau-Gachelin
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

3.  A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1.

Authors:  Sandeep N Wontakal; Xingyi Guo; Britta Will; Minyi Shi; Debasish Raha; Milind C Mahajan; Sherman Weissman; Michael Snyder; Ulrich Steidl; Deyou Zheng; Arthur I Skoultchi
Journal:  PLoS Genet       Date:  2011-06-09       Impact factor: 5.917

4.  Erythropoietin down-regulates stem cell factor receptor (Kit) expression in the leukemic proerythroblast: role of Lyn kinase.

Authors:  Olivier Kosmider; Dorothée Buet; Isabelle Gallais; Nicole Denis; Françoise Moreau-Gachelin
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

Review 5.  Multi-stage Friend murine erythroleukemia: molecular insights into oncogenic cooperation.

Authors:  Françoise Moreau-Gachelin
Journal:  Retrovirology       Date:  2008-11-04       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.